• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to technical biochemistry, in particular, to the preparative isolation of protein antigens of bacteria of the genus Bordetella pertus sis, and can be used in r-krobiology, medicine, and immunology. The aim of the invention is to increase the capacity of affinity sorbents while at the same time increasing the purity of the acceptable antigens. First, soft hydrolysis of fatunink or haptoglobin is carried out to obtain desaturated derivatives, which are fixed on a water-insoluble carrier (organic or inorganic). The culture fluid of Eordetella pertussis bacteria is adsorbed on a.-jKbHHHOM sorbent at pH 6-8, and desorption is carried out either with a buffer solution containing sodium chloride, or with chaotropic agents, or carbonate buffer with a pH of 8.3- 1 5 6 .. i h apt. (P
    公开号:SU1600633A3
    申请号:SU874202442
    申请日:1987-04-15
    公开日:1990-10-15
    发明作者:Бернадетт Жаклин Кентэн-Мийе Мари-Жозе；Арминжон Франсуа
    申请人:Энститю Мерье (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to technical biochemistry and biotechnology, in particular to the preparative isolation of the protein toxin of the bacteria Borrletella .pertussis, and can be used in microbiology, medicine and immunology.
    The aim of the invention is to increase the efficiency of the process and the purity of the excreted toxin.
    The method is carried out as follows.
    First, soft hydrolysis of fetuin or haptoglobin is carried out to obtain desialylated derivatives. These derivatives are then fixed on a water-insoluble carrier (organic or inorganic) to obtain affinity sorbents. These sorbents are used to purify the protein antigens of the Bordetella pertussis bacteria.
    In the process, the pertussis toxin is removed, which is fixed on the affinity carrier, while the F-HA remains in solution, then the pertussis toxin is eluted with the help of a suitable eluent.
    This method is also used for the purification of an enriched F-HA fraction to remove pertussis toxin, which it may contain, and this latter is retained.
    05
    oo with

    cm
    to
    my carrier. Separating the resulting yositephi after contacting the solution with the chromatography material, a purified F-HA-pacTBOp is obtained.
    The initial cleaned solution can be the supernatant culture of bacteria of the genus Bordetella or a partially purified pertussis toxin solution or F-HA.
    To purify pertussis toxin on an affinity carrier using adsorption chromatography, an initial solution is used, the pH of which is adjusted to 6-8, preferably 7. The amount of adsorption chromatography carrier used depends on the initial volume of supernatant and / or the concentration of pertussis toxin in the culture medium 20 or in the fraction used as starting material. The contact is made in a bath or in a column.
    1600633
    ra containing 1 mg / ml of asialofetin, 0.1 M NaHOO and 0.5 M NaCl.
    The mixture was allowed to react overnight with gentle stirring. 125 ml of a 5M ethanolamine solution, pH 8.0, are added to the mixture. After incubating the gel for 4 hours at room temperature, the gel is successively washed with 500 ml of 0.1 M sodium acetate buffer, pH 4.0, containing III NaCL, then 500 ml of 50 t Tris-HCl buffer, pH 7.5, containing sh NaCl. This washing cycle is repeated three times.
    The gel is then washed 3 times with 500 ml of 50 mM Tris-HCl buffer, pH 7.5, in the presence of a preservative such as merthiolus, with a concentration of 1/10000 (parts by volume).
    Sepharose gel - AE coupled to asialopetuine is stored in a buffer such as 50 mM Tris-HC1-buffer, pH 7.5, in the presence of preservatives.
    at 2-30 ° C.
    Dp elution of the pertussis toxin, 25 ta, for example merthiol ta. fixed on an affinity carrier. Used as a ligand, it is possible to use, for example, a buffer solution containing in sufficient concentration of salt and / or classical
    thirty
    chaotropic agents, for example, cogni chloride or carbonate buffer, having a molarity greater than 25 mM and a pH of between 8.3 and 11.6.
    Asialopetuin adsorption chromatography is prepared in the following manner. The aqueous solution of fetuin (fetuin type III, Sigma) is hydrolyzed with 0.05 n. "2504 for 1 h - at. After hydrolysis, the solution is distilled with several volumes of distilled water for 24 hours at + to remove free sialic acids. The solution of asiofeutuin can be concentrated by ultrafiltration using membranes with a separation threshold of 10,000.
    The method is illustrated by the following examples.
    Example 1. Purification of pertussis toxin by adsorption chromatography on sepharose 4B-asiapofetune. , 40
    but). Pertussis toxin adsorption
    on the gel.
    The pertussis toxin enriched fraction obtained after centrifuging and concentrating the bacterial suspension of Bordetella pertussis (phase I) cultured in a 30 L fermenter is passed through a 4 cm diameter chromatographic column containing
    l Sepharose-4B, combined with asialofetuin, with a flow rate of 6 mp / cm / h. Sepharose-4B is coupled with asialofetuin as follows. 30 g of activated CSTg of Sepharose 4B (Pharmacia) is subjected to swelling in 6 l mM HC1 for about 15 minutes. The gel is then washed. 3 times in 6 l 1 mK HC1. 400 ml of a solution, for example merthiolate, is added to the gel. Used as a ligand in
    Asialopetuin adsorption chromatography is prepared in the following manner. The aqueous solution of fetuin (fetuin type III, Sigma) is hydrolyzed with 0.05 n. "2504 for 1 h - at. After hydrolysis, the solution is distilled with several volumes of distilled water for 24 hours at + to remove free sialic acids. The solution of asiofeutuin can be concentrated by ultrafiltration using membranes with a separation threshold of 10,000.
    Removal of sialic acids is controlled by specific colorimetric determination of sialic acids of the protein fraction before and after hydrolysis.
    b). Toxin elution.
    The gel is washed with two column volumes of 50 mM Tris-HCl buffer, 5 i.e. right up to the complete disappearance of the UV-scale at 278, then with one column volume of 50 mM Tris-HCl buffer, pH 7.5, containing 1 M NaCl. Toxin pertussis is eluted with 400 ml of 100 mM carbonate buffer, pH 9.6.
    The optical density and hemagglutinate activity of the cobinex fraction at the exit of the column is measured.
    Contains the active beginning of the fraction, i.e. possessing strong
    magglutinate, non-inhibitory cholesterol activity, is combined,
    The pertussis toxin is then precipitated on ammonium sulfate with a final concentration corresponding to 70% saturation,
    Thus, the purified pertussis toxin causes strong lymphocytes and eats: susceptible (sensitizes) CFW mice to histamine at a dose of 0.04 μg / mouse. The ability of pertussis toxin to form clusters on CHO cells is characterized by a specific activity on the order of 65000-260000, CPU / μg.
    The results of physicochemical analyzes and biological activities (the possible content of contaminants is determined by colorimetrically, DNA, sugar DNAJ determine the content of endotoxin, electrophoresis in SDS or acidic media, etc.) confirm the homogeneity of the finished preparation, including purified the beginning.
    Analyzes of the pertussis toxin content in the initial culture supernatant and in the final sediment show the yield after purification above 90%.
    Example 2. Purification of the pertussis toxin by adsorbed chromatography on spherosil-OEAE-dextran-asalofetuine.
    but). Adsorption of toxin on adsorption chromatography gel.
    pH of the fraction obtained after centrifuging and concentrating the suspension of Bordetella pertussis suspension (phase 1)

    adjusted to 7 by the addition of 5 n. hydrochloric acid solution. The fraction is passed through a 2 cm diameter column containing 60 ml of a Spherosil-BEAE-dextran carrier, combined with asialofetuine, at a rate of 60 mp / cm / h.
    Spherosil-BEA-dextran (carrier formed by XOS 005 silicon dioxide beads coated with a minimum of cross-linked DEAE-dextran) is combined with asialofetuine in the following manner.
    Spherosil-BEAE-dextran is subjected to careful oxidation to obtain aldehyde functions capable of reacting with the aline groups of the ligand. Asialofetuin as a solution with a concentration of 4 mg / ml in YUMM phosphate buffer, pH 8.0, is introduced into
    contact with gel for 15 h at room temperature. Gbl is then washed with the following solutions: 10 W phosphate buffer, pH 8.0, 20 g / l glycokol, 0.17 mM NaCl, 0.05 M sodium citrate, pH 2.8, i n. HCi;
    ABOUT
    b). Pertus10 Toxin Elution
    five
    0
    five
    0
    five
    sis.
    The gel is washed with 120 ml of 50 mM Tris-HC1 buffer, pH 7.5, then 70 ml of 50 mM Tris HC1 buffer containing 1 M NaCl. Pertussis toxin is diluted with 50 mM Tris-HCl buffer, pH 7.5, containing 4 M MgCl. The optical density at 288 nm and the hemaggutinant activity of the fractions collected at the outlet of the column are measured. Containing 20 is the active principle of the fraction possessing increased hemagglutinant activity not cholesterol inhibited are combined.
    The resulting mixture is desalted by filtration through a gel in a column with Sephadex C-25 {7.5 i 45 cm, Pharmacia), equilibrated with a buffer of 50 mM Tris-HCl, pH 7.5. The elution is carried out using the same buffer.
    The optical density at 278 nm and the hemagglutinant activity of the fractions collected at the outlet of the column are measured. Toxin-containing pertussis fractions, i.e. possessing increased hemagglutinant activity are combined.
    The active onset is precipitated on ammonium sulphate by slowly adding D7r {NFg) SOED per 100 ml of solution while stirring. An analysis of the biological and physicochemical properties shows that the product obtained is a highly read active ingredient.
    Example 3. Removal of traces of pertussis toxin from the enriched F-HA fraction.
    Methods for purifying F-HA include the step of desorbing F-HA from a chromatographic carrier, for example hydroxyapatite, with 100 phosphate buffer, pH 7.0, containing 0.5 M NaCl.
    Optical density at 278 nm and hemagglutinant activity of the fractions collected at the outlet of the column with oxyapatite are measured. Fractions containing F-HAj i. possessed hemagglutinant active0
    five
    hereby, and the inhibitor {slesters, are combined,
    In order to remove possibly traces of pertussis toxin, a mixture of fractions containing F-fIA is passed through a column with 4B-asialofetuin sepharose. F-HA is eluted directly, while a possible trace of: toxin is retained to the column.
    F-HA is then precipitated with ammonium sulfate by adding, slowly and with stirring, 47 g (Sd) 304 per 100 ml of solution.
    Thus, purified F-HA does not cause lymphocytosis, but histamine susceptibility to a dose of 100 µg / Ms1. Pu concentrate 100.. F-HA e causes my; sifikatsii c. the cell layer formed by ovarian ovary cells, i.e. no formation of cell clusters (clusters) characteristic of the presence of the toxin {pertussis. Its specific hemaggutinant activity, measured on geese erythrocytes, is about 250000-500000 units, NA / mg yi): This activity is completely inhibited by cholesterol.
    Example 4. Comparative study of the ability of pertussis toxin on carriers of fetuin-based adsorption chromatography and asialofetuine.
    A gel for adsorption chromatography is prepared by immobilizing asialofetuin on activated CNBt (Pharmacia) Sepharose-4B according to the method described in Example 1,
    five
    0
    In parallel, gel for adsorption chromatography with fetuin,.
    Fixation of fetuin and fixation of asialofetuin are carried out under identical experimental conditions to obtain the densities of the compared ligands on the gels.
    Each experiment is carried out in parallel on two types of carriers, put into contact with the same volume of culture supernatant containing pertussis toxin. The amount of pertussis toxin eluted is determined by protein analysis and ELISA.
    A comparative study of the suitability of Sheluche 11; s gels. The relative capacity of the gel containing fetuin is 79% of the capacity of the gel containing asialofetuin.
    权利要求:
    Claims (2)
    [1]
    1. The method of purification of the protein toxin of the bacteria Bordetella pertussis using affinity chromatography is different in that the affinity sorbent containing the stationary ligand is a desyapated glycoprotein using a chain to increase the process efficiency and purity of the isolated toxin.
    [2]
    2. Method pop. , differing from the fact that they use an affinity sorbent containing asialopethein or aspalogaptoglobin as a desialylated glycoprotein. .
    类似技术:
    公开号 | 公开日 | 专利标题
    Er-el et al.1972|Hydrocarbon-coated sepharoses. Use in the purification of glycogen phosphorylase
    US4673734A|1987-06-16|Porous mineral support coated with an aminated polysaccharide polymer
    US4138287A|1979-02-06|Purifying and isolating method for hepatitis virus to use in preparing vaccine
    SU1431691A3|1988-10-15|Method of producing glycoprotein
    CN1015512B|1992-02-19|Tangential flow affinity ultrafiltration
    Nachman et al.1992|Membrane-based receptor affinity chromatography
    US4359389A|1982-11-16|Method for the purification of interferon
    US5234991A|1993-08-10|Porous mineral support coated with an aminated polysaccharide polymer
    SU1600633A3|1990-10-15|Method of purifying protein toxin of bordetella petrusis bacteria
    US5280109A|1994-01-18|Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
    US4440675A|1984-04-03|Human immune interferon
    CA1237998A|1988-06-14|Method for purification of filamentous hemagglutinin
    SU1523046A3|1989-11-15|Method of purifying human beta-interferon
    US4168261A|1979-09-18|Method for the purification of interferon using porous glass beads
    US4382027A|1983-05-03|Purification of human immune interferon
    US4485038A|1984-11-27|Method for the production and purification of human leukocyte interferon
    US4743551A|1988-05-10|Purification of microbial rennet from Mucor miehei
    US3925152A|1975-12-09|Virus separation
    Hagiwara et al.2005|High-performance purification of gelsolin from plasma using anion-exchange porous hollow-fiber membrane
    SU644796A1|1979-01-30|Method of purifying proteolytic ferments
    JP3508149B2|2004-03-22|Human serum albumin and method for producing the same
    RU2145610C1|2000-02-20|Method of purification of human recombinant erythropoietin
    JP4154743B2|2008-09-24|Method for purifying interleukin-6 receptor
    CA1239104A|1988-07-12|Method for the purification of lpf-ha
    SU1175965A1|1985-08-30|Method of separating urokinase from biologucal sources
    同族专利:
    公开号 | 公开日
    AU7158087A|1987-10-22|
    JPS62253396A|1987-11-05|
    DE242302T1|1988-06-09|
    ZA872711B|1987-10-05|
    JPH0826080B2|1996-03-13|
    AU603794B2|1990-11-29|
    ES2000434B3|1991-04-16|
    EP0242302B1|1990-10-31|
    FR2597605A1|1987-10-23|
    US5045203A|1991-09-03|
    EP0242302A1|1987-10-21|
    CA1295985C|1992-02-18|
    FR2597605B1|1989-06-23|
    AT57936T|1990-11-15|
    DE3765822D1|1990-12-06|
    LU90380I2|1999-05-31|
    GR880300042T1|1988-10-18|
    GR3001376T3|1992-09-11|
    ES2000434A4|1988-03-01|
    US4985144A|1991-01-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    SU547104A1|1973-12-21|1985-03-30|Московский ордена Ленина и ордена Трудового Красного Знамени химико-технологический институт им.Д.И.Менделеева|Method of obtaining sorbent for hemoadsorption|
    US4225487A|1974-05-31|1980-09-30|Pedro Cuatrecasas|Affinity chromatography of Vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers|
    US4125492A|1974-05-31|1978-11-14|Pedro Cuatrecasas|Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers|
    US4010251A|1974-12-16|1977-03-01|Green Allan M|Scanning agent composition and use in imaging liver and for biliary function|
    FR2403098B1|1977-09-19|1980-06-13|Merieux Inst|
    US4247452A|1978-03-01|1981-01-27|The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland|Purification of pertussis haemagglutinins|
    US4416872A|1982-03-17|1983-11-22|The United States Of America As Represented By The Secretary Of The Army|Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates|
    US4466951A|1982-11-12|1984-08-21|University Of California|Intracellular trapping of therapeutics or tracer agents|
    SE445649B|1983-06-08|1986-07-07|Jorgen Hermansson|APPLICATION OF A FIXED BEARER WITH IMMOBILIZED OROSOMUCOID FOR SEPARATION, PROCEDURE FOR PRODUCING SEPARATION MATERIAL, SEPARATION DEVICE AND SEPARATION MATERIAL|
    JPS6262153B2|1983-11-01|1987-12-24|Kagaku Oyobi Ketsusei Ryoho Kenkyusho|
    JPH0574576B2|1984-09-22|1993-10-18|Chemo Sero Therapeut Res Inst|EP0218859A3|1985-10-11|1989-09-06|International Business Machines Corporation|Signal processor communication interface|
    AU613387B2|1987-08-13|1991-08-01|Carl-Zeiss-Stiftung Trading As Schott Glaswerke|An inorganic carrier element comprising an amine-containing surface layer for the immobilization of microorganisms or cells, a process for the preparation thereof|
    US5445817A|1992-08-21|1995-08-29|The United States Of America As Represented By The Department Of Health And Human Services|Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines|
    JPWO2004036216A1|2002-10-18|2006-02-16|独立行政法人科学技術振興機構|Method for measuring interaction between sugar chain-sugar chain binding protein and use thereof|
    US7402243B2|2004-09-10|2008-07-22|Dionex Corporation|Organosilanes and substrate bonded with same|
    US7468130B2|2005-02-15|2008-12-23|Dionex Corporation|Organosilanes and substrates covalently bonded with same and methods for synthesis and use same|
    US7557232B2|2007-05-25|2009-07-07|Dionex Corporation|Compositions useful as chromatography stationary phases|
    CN103547589A|2011-03-29|2014-01-29|葛兰素史密斯克莱有限责任公司|Buffer system for protein purification|
    WO2019189473A1|2018-03-27|2019-10-03|日本精工株式会社|Steering device|
    KR102362777B1|2018-03-27|2022-02-15|주식회사 녹십자|Method for obtaining bordetella pertussis related proteins comprising affinity chromatography|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR8605457A|FR2597605B1|1986-04-16|1986-04-16|NOVEL MATERIAL FOR AFFINITY CHROMATOGRAPHY AND ITS APPLICATION TO THE SEPARATION AND PURIFICATION OF PROTEIN ANTIGENS FROM BORDETELLA GENUS|
    [返回顶部]